ArticleDiscover oncology2026
A case report of carotid body tumor with rare thoracic vertebral metastasis and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant carotid body tumor (CBT), a type of carotid body paraganglioma (PGL), is defined by the presence of distant metastasis; histology alone cannot reliably distinguish benign from malignant CBT. We present a 70-year-old female patient who had been suspected of having CBT for more than 10 years without specific treatment, and complained of abdominal pain for 6 months. Contrast-enhanced MRI and CT revealed a T11 vertebral lesion, followed by percutaneous biopsy of the lesion, which showed atypical cell nests. Immunohistochemical staining was positive for CD56, CgA, Syn and S-100, and negative for cytokeratin. A diagnosis of metastatic PGL consistent with malignant CBT was established. The patient received palliative radiotherapy to the T11 vertebra (20 Gy/5 fractions), which was well tolerated without obvious radiation-related adverse reactions. At the 12-month follow-up, the patient remained alive.
conclusionIn this case, a highly suggestive diagnosis of PGL (malignant CBT) with bone metastasis was made based on imaging features, T11 vertebral biopsy, and immunohistochemical results. It provides a reference for radiotherapy in similar clinical settings. For unresectable thoracic vertebral metastases, palliative radiotherapy (20 Gy/5 fractions) can be considered after clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.